Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Development of a qPCR platform for quantification of the five bacteriophages within bacteriophage cocktail 2 (BFC2).

Duyvejonck H, Merabishvili M, Pirnay JP, De Vos D, Verbeken G, Van Belleghem J, Gryp T, De Leenheer J, Van der Borght K, Van Simaey L, Vermeulen S, Van Mechelen E, Vaneechoutte M.

Sci Rep. 2019 Sep 25;9(1):13893. doi: 10.1038/s41598-019-50461-0.

2.

Bacteriophage Application for Difficult-to-treat Musculoskeletal Infections: Development of a Standardized Multidisciplinary Treatment Protocol.

Onsea J, Soentjens P, Djebara S, Merabishvili M, Depypere M, Spriet I, De Munter P, Debaveye Y, Nijs S, Vanderschot P, Wagemans J, Pirnay JP, Lavigne R, Metsemakers WJ.

Viruses. 2019 Sep 23;11(10). pii: E891. doi: 10.3390/v11100891.

3.

Processing Phage Therapy Requests in a Brussels Military Hospital: Lessons Identified.

Djebara S, Maussen C, De Vos D, Merabishvili M, Damanet B, Pang KW, De Leenheer P, Strachinaru I, Soentjens P, Pirnay JP.

Viruses. 2019 Mar 17;11(3). pii: E265. doi: 10.3390/v11030265.

4.

Correction to: Biological tests carried out on serum/plasma samples from donors of human body material for transplantation: Belgian experience and practical recommendations.

Padalko E, Lagrou K, Delforge ML, Jansens H, Ectors N, Pirnay JP, Klykens J, Sokal E, Muylle L, Libois A, Vanderkelen A, Verbeken G, Matthys C, Goossens D, Hanssens G, Baltes M, Beele H.

Cell Tissue Bank. 2018 Dec;19(4):835-836. doi: 10.1007/s10561-018-9728-8.

5.

Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial.

Jault P, Leclerc T, Jennes S, Pirnay JP, Que YA, Resch G, Rousseau AF, Ravat F, Carsin H, Le Floch R, Schaal JV, Soler C, Fevre C, Arnaud I, Bretaudeau L, Gabard J.

Lancet Infect Dis. 2019 Jan;19(1):35-45. doi: 10.1016/S1473-3099(18)30482-1. Epub 2018 Oct 3.

PMID:
30292481
6.

Biological tests carried out on serum/plasma samples from donors of human body material for transplantation: Belgian experience and practical recommendations.

Padalko E, Lagrou K, Delforge ML, Jansens H, Ectors N, Pirnay JP, Klykens J, Sokal E, Muylle L, Libois A, Vanderkelen A, Verbeken G, Matthys C, Goossens D, Hanssens G, Baltes M, Beele H.

Cell Tissue Bank. 2018 Dec;19(4):681-695. doi: 10.1007/s10561-018-9721-2. Epub 2018 Aug 29. Erratum in: Cell Tissue Bank. 2018 Oct 26;:.

7.

Prevalence of Anaplasma phagocytophilum in humans in Belgium for the period 2013-2016.

Hing M, Van Den Bossche D, Lernout T, Cochez C, Pirnay JP, Heuninckx W.

Acta Clin Belg. 2019 Aug;74(4):280-285. doi: 10.1080/17843286.2018.1491928. Epub 2018 Jul 20.

PMID:
30029581
8.

Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy-Part II.

Expert round table on acceptance and re-implementation of bacteriophage therapy, Sybesma W, Rohde C, Bardy P, Pirnay JP, Cooper I, Caplin J, Chanishvili N, Coffey A, De Vos D, Scholz AH, McCallin S, Püschner HM, Pantucek R, Aminov R, Doškař J, Kurtbӧke Dİ.

Antibiotics (Basel). 2018 Apr 23;7(2). pii: E35. doi: 10.3390/antibiotics7020035.

9.

Expert Opinion on Three Phage Therapy Related Topics: Bacterial Phage Resistance, Phage Training and Prophages in Bacterial Production Strains.

Rohde C, Resch G, Pirnay JP, Blasdel BG, Debarbieux L, Gelman D, Górski A, Hazan R, Huys I, Kakabadze E, Łobocka M, Maestri A, Almeida GMF, Makalatia K, Malik DJ, Mašlaňová I, Merabishvili M, Pantucek R, Rose T, Štveráková D, Van Raemdonck H, Verbeken G, Chanishvili N.

Viruses. 2018 Apr 5;10(4). pii: E178. doi: 10.3390/v10040178.

10.

Selection of Potential Therapeutic Bacteriophages that Lyse a CTX-M-15 Extended Spectrum β-Lactamase Producing Salmonella enterica Serovar Typhi Strain from the Democratic Republic of the Congo.

Kakabadze E, Makalatia K, Grdzelishvili N, Bakuradze N, Goderdzishvili M, Kusradze I, Phoba MF, Lunguya O, Lood C, Lavigne R, Jacobs J, Deborggraeve S, De Block T, Van Puyvelde S, Lee D, Coffey A, Sedrakyan A, Soentjens P, De Vos D, Pirnay JP, Chanishvili N.

Viruses. 2018 Apr 3;10(4). pii: E172. doi: 10.3390/v10040172.

11.

The Magistral Phage.

Pirnay JP, Verbeken G, Ceyssens PJ, Huys I, De Vos D, Ameloot C, Fauconnier A.

Viruses. 2018 Feb 6;10(2). pii: E64. doi: 10.3390/v10020064. Review.

12.

Bacteriophage Production in Compliance with Regulatory Requirements.

Pirnay JP, Merabishvili M, Van Raemdonck H, De Vos D, Verbeken G.

Methods Mol Biol. 2018;1693:233-252. doi: 10.1007/978-1-4939-7395-8_18.

PMID:
29119444
13.

Guidelines to Compose an Ideal Bacteriophage Cocktail.

Merabishvili M, Pirnay JP, De Vos D.

Methods Mol Biol. 2018;1693:99-110. doi: 10.1007/978-1-4939-7395-8_9.

PMID:
29119435
14.

Stability of bacteriophages in burn wound care products.

Merabishvili M, Monserez R, van Belleghem J, Rose T, Jennes S, De Vos D, Verbeken G, Vaneechoutte M, Pirnay JP.

PLoS One. 2017 Jul 27;12(7):e0182121. doi: 10.1371/journal.pone.0182121. eCollection 2017.

15.

[Beyond antibiotic therapy - Future antiinfective strategies - Update 2017].

Vogt D, Sperling S, Tkhilaishvili T, Trampuz A, Pirnay JP, Willy C.

Unfallchirurg. 2017 Jul;120(7):573-584. doi: 10.1007/s00113-017-0374-6. Review. German.

PMID:
28643099
16.

Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report.

Jennes S, Merabishvili M, Soentjens P, Pang KW, Rose T, Keersebilck E, Soete O, François PM, Teodorescu S, Verween G, Verbeken G, De Vos D, Pirnay JP.

Crit Care. 2017 Jun 4;21(1):129. doi: 10.1186/s13054-017-1709-y. No abstract available.

17.

Antimicrobial resistance and genomic rep-PCR fingerprints of Pseudomonas aeruginosa strains from animals on the background of the global population structure.

Serrano I, Oliveira M, Santos JP, Bilocq F, Leitão A, Tavares L, Pirnay JP, De Vos D.

BMC Vet Res. 2017 Feb 21;13(1):58. doi: 10.1186/s12917-017-0977-8.

18.

The Developing World Urgently Needs Phages to Combat Pathogenic Bacteria.

Nagel TE, Chan BK, De Vos D, El-Shibiny A, Kang'ethe EK, Makumi A, Pirnay JP.

Front Microbiol. 2016 Jun 8;7:882. doi: 10.3389/fmicb.2016.00882. eCollection 2016. No abstract available.

19.

Molecular Epidemiology and Clinical Impact of Acinetobacter calcoaceticus-baumannii Complex in a Belgian Burn Wound Center.

De Vos D, Pirnay JP, Bilocq F, Jennes S, Verbeken G, Rose T, Keersebilck E, Bosmans P, Pieters T, Hing M, Heuninckx W, De Pauw F, Soentjens P, Merabishvili M, Deschaght P, Vaneechoutte M, Bogaerts P, Glupczynski Y, Pot B, van der Reijden TJ, Dijkshoorn L.

PLoS One. 2016 May 25;11(5):e0156237. doi: 10.1371/journal.pone.0156237. eCollection 2016.

20.

Bacteriophage therapy: Fast-forward to the past lessons identified from the advanced therapy regulation.

Verbeken G, Huys I, Ceulemans C, Jennes S, De Vos D, Pirnay JP.

Burns. 2016 Feb;42(1):11-12. doi: 10.1016/j.burns.2015.10.022. Epub 2015 Dec 17. No abstract available.

PMID:
26702564
21.

Increase of efflux-mediated resistance in Pseudomonas aeruginosa during antibiotic treatment in patients suffering from nosocomial pneumonia.

Riou M, Avrain L, Carbonnelle S, El Garch F, Pirnay JP, De Vos D, Plésiat P, Tulkens PM, Van Bambeke F.

Int J Antimicrob Agents. 2016 Jan;47(1):77-83. doi: 10.1016/j.ijantimicag.2015.11.004. Epub 2015 Nov 26.

PMID:
26691019
22.

Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework.

Verbeken G, Huys I, De Vos D, De Coninck A, Roseeuw D, Kets E, Vanderkelen A, Draye JP, Rose T, Jennes S, Ceulemans C, Pirnay JP.

FEMS Microbiol Lett. 2016 Feb;363(4). pii: fnv241. doi: 10.1093/femsle/fnv241. Epub 2015 Dec 16.

PMID:
26678555
23.

A bacteriophage journey at the European Medicines Agency.

Debarbieux L, Pirnay JP, Verbeken G, De Vos D, Merabishvili M, Huys I, Patey O, Schoonjans D, Vaneechoutte M, Zizi M, Rohde C.

FEMS Microbiol Lett. 2016 Jan;363(2):fnv225. doi: 10.1093/femsle/fnv225. Epub 2015 Dec 10. No abstract available.

24.

Clinical utilization of genomics data produced by the international Pseudomonas aeruginosa consortium.

Freschi L, Jeukens J, Kukavica-Ibrulj I, Boyle B, Dupont MJ, Laroche J, Larose S, Maaroufi H, Fothergill JL, Moore M, Winsor GL, Aaron SD, Barbeau J, Bell SC, Burns JL, Camara M, Cantin A, Charette SJ, Dewar K, Déziel É, Grimwood K, Hancock RE, Harrison JJ, Heeb S, Jelsbak L, Jia B, Kenna DT, Kidd TJ, Klockgether J, Lam JS, Lamont IL, Lewenza S, Loman N, Malouin F, Manos J, McArthur AG, McKeown J, Milot J, Naghra H, Nguyen D, Pereira SK, Perron GG, Pirnay JP, Rainey PB, Rousseau S, Santos PM, Stephenson A, Taylor V, Turton JF, Waglechner N, Williams P, Thrane SW, Wright GD, Brinkman FS, Tucker NP, Tümmler B, Winstanley C, Levesque RC.

Front Microbiol. 2015 Sep 29;6:1036. doi: 10.3389/fmicb.2015.01036. eCollection 2015.

25.

Pre-adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosa cystic fibrosis bacterial isolates.

Friman VP, Soanes-Brown D, Sierocinski P, Molin S, Johansen HK, Merabishvili M, Pirnay JP, De Vos D, Buckling A.

J Evol Biol. 2016 Jan;29(1):188-98. doi: 10.1111/jeb.12774. Epub 2015 Nov 9.

26.

The Widespread Multidrug-Resistant Serotype O12 Pseudomonas aeruginosa Clone Emerged through Concomitant Horizontal Transfer of Serotype Antigen and Antibiotic Resistance Gene Clusters.

Thrane SW, Taylor VL, Freschi L, Kukavica-Ibrulj I, Boyle B, Laroche J, Pirnay JP, Lévesque RC, Lam JS, Jelsbak L.

mBio. 2015 Sep 22;6(5):e01396-15. doi: 10.1128/mBio.01396-15.

27.

Correlation between cytotoxicity induced by Pseudomonas aeruginosa clinical isolates from acute infections and IL-1β secretion in a model of human THP-1 monocytes.

Anantharajah A, Buyck JM, Faure E, Glupczynski Y, Rodriguez-Villalobos H, De Vos D, Pirnay JP, Bilocq F, Guery B, Tulkens PM, Mingeot-Leclercq MP, Van Bambeke F.

Pathog Dis. 2015 Oct;73(7). pii: ftv049. doi: 10.1093/femspd/ftv049. Epub 2015 Jul 22.

28.

Access to human tissues for research and product development: From EU regulation to alarming legal developments in Belgium.

Pirnay JP, Baudoux E, Cornu O, Delforge A, Delloye C, Guns J, Heinen E, Van den Abbeel E, Vanderkelen A, Van Geyt C, van Riet I, Verbeken G, De Sutter P, Verlinden M, Huys I, Cockbain J, Chabannon C, Dierickx K, Schotsmans P, De Vos D, Rose T, Jennes S, Sterckx S.

EMBO Rep. 2015 May;16(5):557-62. doi: 10.15252/embr.201540070. Epub 2015 Apr 7. No abstract available.

29.

Recellularizing of human acellular dermal matrices imaged by high-definition optical coherence tomography.

Boone MA, Draye JP, Verween G, Aiti A, Pirnay JP, Verbeken G, De Vos D, Rose T, Jennes S, Jemec GB, Del Marmol V.

Exp Dermatol. 2015 May;24(5):349-54. doi: 10.1111/exd.12662.

PMID:
25704791
30.

Quality and safety requirements for sustainable phage therapy products.

Pirnay JP, Blasdel BG, Bretaudeau L, Buckling A, Chanishvili N, Clark JR, Corte-Real S, Debarbieux L, Dublanchet A, De Vos D, Gabard J, Garcia M, Goderdzishvili M, Górski A, Hardcastle J, Huys I, Kutter E, Lavigne R, Merabishvili M, Olchawa E, Parikka KJ, Patey O, Pouilot F, Resch G, Rohde C, Scheres J, Skurnik M, Vaneechoutte M, Van Parys L, Verbeken G, Zizi M, Van den Eede G.

Pharm Res. 2015 Jul;32(7):2173-9. doi: 10.1007/s11095-014-1617-7. Epub 2015 Jan 14.

31.

Experimental phage therapy of burn wound infection: difficult first steps.

Rose T, Verbeken G, Vos DD, Merabishvili M, Vaneechoutte M, Lavigne R, Jennes S, Zizi M, Pirnay JP.

Int J Burns Trauma. 2014 Oct 26;4(2):66-73. eCollection 2014.

32.

O serotype-independent susceptibility of Pseudomonas aeruginosa to lectin-like pyocins.

Ghequire MG, Dingemans J, Pirnay JP, De Vos D, Cornelis P, De Mot R.

Microbiologyopen. 2014 Dec;3(6):875-84. doi: 10.1002/mbo3.210. Epub 2014 Sep 16.

33.

Characterization of newly isolated lytic bacteriophages active against Acinetobacter baumannii.

Merabishvili M, Vandenheuvel D, Kropinski AM, Mast J, De Vos D, Verbeken G, Noben JP, Lavigne R, Vaneechoutte M, Pirnay JP.

PLoS One. 2014 Aug 11;9(8):e104853. doi: 10.1371/journal.pone.0104853. eCollection 2014.

34.

Real-time three-dimensional imaging of epidermal splitting and removal by high-definition optical coherence tomography.

Boone M, Draye JP, Verween G, Pirnay JP, Verbeken G, De Vos D, Rose T, Jennes S, Jemec GB, Del Marmol V.

Exp Dermatol. 2014 Oct;23(10):725-30. doi: 10.1111/exd.12516.

PMID:
25047067
35.

Engineered endolysin-based "Artilysins" to combat multidrug-resistant gram-negative pathogens.

Briers Y, Walmagh M, Van Puyenbroeck V, Cornelissen A, Cenens W, Aertsen A, Oliveira H, Azeredo J, Verween G, Pirnay JP, Miller S, Volckaert G, Lavigne R.

mBio. 2014 Jul 1;5(4):e01379-14. doi: 10.1128/mBio.01379-14.

36.

Effectiveness of bacteriophages in the sputum of cystic fibrosis patients.

Saussereau E, Vachier I, Chiron R, Godbert B, Sermet I, Dufour N, Pirnay JP, De Vos D, Carrié F, Molinari N, Debarbieux L.

Clin Microbiol Infect. 2014 Dec;20(12):O983-90. doi: 10.1111/1469-0691.12712. Epub 2014 Jul 26.

37.

Taking bacteriophage therapy seriously: a moral argument.

Verbeken G, Huys I, Pirnay JP, Jennes S, Chanishvili N, Scheres J, Górski A, De Vos D, Ceulemans C.

Biomed Res Int. 2014;2014:621316. doi: 10.1155/2014/621316. Epub 2014 Apr 29.

38.

Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa.

Briers Y, Walmagh M, Grymonprez B, Biebl M, Pirnay JP, Defraine V, Michiels J, Cenens W, Aertsen A, Miller S, Lavigne R.

Antimicrob Agents Chemother. 2014 Jul;58(7):3774-84. doi: 10.1128/AAC.02668-14. Epub 2014 Apr 21.

39.

Call for a dedicated European legal framework for bacteriophage therapy.

Verbeken G, Pirnay JP, Lavigne R, Jennes S, De Vos D, Casteels M, Huys I.

Arch Immunol Ther Exp (Warsz). 2014 Apr;62(2):117-29. doi: 10.1007/s00005-014-0269-y. Epub 2014 Feb 6. Review.

40.

Developing an international Pseudomonas aeruginosa reference panel.

De Soyza A, Hall AJ, Mahenthiralingam E, Drevinek P, Kaca W, Drulis-Kawa Z, Stoitsova SR, Toth V, Coenye T, Zlosnik JE, Burns JL, Sá-Correia I, De Vos D, Pirnay JP, Kidd TJ, Reid D, Manos J, Klockgether J, Wiehlmann L, Tümmler B, McClean S, Winstanley C; EU FP7 funded COST Action BM1003 “Cell surface virulence determinants of cystic fibrosis pathogens”.

Microbiologyopen. 2013 Dec;2(6):1010-23. doi: 10.1002/mbo3.141. Epub 2013 Nov 11.

41.

Paving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy.

Huys I, Pirnay JP, Lavigne R, Jennes S, De Vos D, Casteels M, Verbeken G.

EMBO Rep. 2013 Nov;14(11):951-4. doi: 10.1038/embor.2013.163. Epub 2013 Oct 18. No abstract available.

42.

Business oriented EU human cell and tissue product legislation will adversely impact Member States' health care systems.

Pirnay JP, Vanderkelen A, De Vos D, Draye JP, Rose T, Ceulemans C, Ectors N, Huys I, Jennes S, Verbeken G.

Cell Tissue Bank. 2013 Dec;14(4):525-60. doi: 10.1007/s10561-013-9397-6. Epub 2013 Sep 20.

43.

Stability of Staphylococcus aureus phage ISP after freeze-drying (lyophilization).

Merabishvili M, Vervaet C, Pirnay JP, De Vos D, Verbeken G, Mast J, Chanishvili N, Vaneechoutte M.

PLoS One. 2013 Jul 2;8(7):e68797. doi: 10.1371/journal.pone.0068797. Print 2013.

44.

Cleanrooms and tissue banking how happy I could be with either GMP or GTP?

Klykens J, Pirnay JP, Verbeken G, Giet O, Baudoux E, Jashari R, Vanderkelen A, Ectors N.

Cell Tissue Bank. 2013 Dec;14(4):571-8. doi: 10.1007/s10561-012-9355-8. Epub 2013 Jan 4.

45.

Selection and characterization of a candidate therapeutic bacteriophage that lyses the Escherichia coli O104:H4 strain from the 2011 outbreak in Germany.

Merabishvili M, De Vos D, Verbeken G, Kropinski AM, Vandenheuvel D, Lavigne R, Wattiau P, Mast J, Ragimbeau C, Mossong J, Scheres J, Chanishvili N, Vaneechoutte M, Pirnay JP.

PLoS One. 2012;7(12):e52709. doi: 10.1371/journal.pone.0052709. Epub 2012 Dec 21.

46.

Evaluation of oprI and oprL genes as molecular markers for the genus Pseudomonas and their use in studying the biodiversity of a small Belgian River.

Matthijs S, Coorevits A, Gebrekidan TT, Tricot C, Wauven CV, Pirnay JP, De Vos P, Cornelis P.

Res Microbiol. 2013 Apr;164(3):254-61. doi: 10.1016/j.resmic.2012.12.001. Epub 2012 Dec 12.

PMID:
23246592
47.

Beware of the commercialization of human cells and tissues: situation in the European Union.

Pirnay JP, Vanderkelen A, Ectors N, Delloye C, Dufrane D, Baudoux E, Van Brussel M, Casaer MP, De Vos D, Draye JP, Rose T, Jennes S, Neirinckx P, Laire G, Zizi M, Verbeken G.

Cell Tissue Bank. 2012 Aug;13(3):487-98. doi: 10.1007/s10561-012-9323-3. Epub 2012 Jun 21.

48.

Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae.

Hall AR, De Vos D, Friman VP, Pirnay JP, Buckling A.

Appl Environ Microbiol. 2012 Aug;78(16):5646-52. doi: 10.1128/AEM.00757-12. Epub 2012 Jun 1.

49.

Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine.

Verbeken G, Pirnay JP, De Vos D, Jennes S, Zizi M, Lavigne R, Casteels M, Huys I.

Arch Immunol Ther Exp (Warsz). 2012 Jun;60(3):161-72. doi: 10.1007/s00005-012-0175-0. Epub 2012 Apr 17. Review.

PMID:
22527355
50.

Schistosomiasis in Belgian military personnel returning from the Democratic Republic of Congo.

Aerssens C, De Vos D, Pirnay JP, Yansouni C, Clerinx J, Van Gompel A, Soentjens P.

Mil Med. 2011 Nov;176(11):1341-6.

PMID:
22165667

Supplemental Content

Loading ...
Support Center